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Background
The field of T cell therapy of cancer holds great promise,
as demonstrated by results obtained in Chimeric Antigen
Receptor (CAR) modified T cell therapy of CD19+ leuke-
mia. However, these anti-tumor effects are often limited
by T cell tolerance and the immunosuppressive tumor
microenvironment. Oncolytic viruses armed with immu-
nostimulatory molecules constitute a potent form of
immunotherapy. In essence, the danger signal caused by
virus replication, coupled with the actions of the trans-
gene, and effective presentation of tumor epitopes by
lysis of the cells, results in a personalized cancer vaccine,
manufactured for each patient in their tumor.
Previously, we have identified interleukin 2 (IL-2) and
Tumor Necrosis Factor alpha (TNF-a) as the most pro-
mising factors to stimulate the graft used in adoptive
T cell therapy. Both cytokines are important activators of
immune cells and also known for their direct anti-tumor
properties. Therefore, we aimed to enhance the efficacy of
ACT by coupling it with adenoviruses coding for immu-
nostimulatory cytokines. Notably, these cytokines can
cause severe side effects when administered systemically.
Previously, we and others have achieved long lasting, high
level cytokine expression locally but low level systemically
when using armed oncolytic viruses in vivo.
Methods
Therefore, we developed oncolytic adenoviruses expres-
sing one or both above mentioned human cytokines
(Ad5/3-E2F-D24-hTNF-a, Ad5/3-E2F-D24-hIL-2 and
Ad5/3-E2F-D24-hTNF-a-IRES-hIL-2). For more detailed
immunological studies in immune competent mouse
models, we constructed non-replicative adenoviruses
with murine cytokines (Ad5-CMV-mIL-2 and Ad5-
CMV-mTNF-a). These viruses were studied in combina-
tion with adoptive transfer of OT-1 TCR transgenic
T cells to treat C57BL/6 mice bearing B16-OVA mela-
noma tumors. The animals were administered intraperi-
toneally with CD8+-enriched OT-1 cells with or without
intratumoral injections of cytokine-coding viruses.
Results
Combination treatment with Ad5-CMV-mIL-2 and OT-1
resulted in statistically significant anti-tumor efficacy when
compared with either monotherapy or untreated control.
In further experiments a triple combination of Ad5-CMV-
mIL-2 + Ad5-CMV-mTNF-a and OT-1 T cells improved
anti-tumor efficacy was observed over dual agent thera-
pies. Furthermore, in mice bearing two tumors we saw
abscopal effect when only one of the tumors was injected
with cytokine encoding viruses but reduction in tumor
size was detected also in the non-injected tumor.
Conclusions
In summary, these results support the further develop-
ment of cytokine-armed adenoviruses as facilitators of
adoptive T cell therapy.
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